Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Antibody antagonists of the insulinotropic receptor GIPR prevent weight gain in obese animal models, and the effect is enhanced by GLP-1R agonists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combined, the SURPASS and SURMOUNT trials have verified the safety of tirzepatide to be consistent with GLP-1R agonists, along with its enhanced efficacy at maximal doses of 5, 10 and 15 mg (Table 1)132-136,143,145-147”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [146]
In the citing paper
“agonists and antagonists of the GIP receptor (GIPR) are currently in development, both of which have paradoxically demonstrated the ability to potentiate the weight reduction of GLP-1R agonists in preclinical models [[32], [33], [34], [35], [36], [37]]”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [33]
In the citing paper
“Neutralizing GIPR antibodies, which are presumably sequestered to the periphery, reduce body weight in an independent manner to food intake and modify energetic substrate utilization in vivo [33]”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [33]
In the citing paper
“The combination of an anti-GIPR monoclonal antibody (mAb) and a GLP-1RA has been shown to mediate more pronounced weight loss than either agent alone in preclinical obesity models33.”
From A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings (2024) · cites this paper as [33]
In the citing paper
“However, it has been shown in animal models that GIP RAs potentiates GLP-1-induced weight loss and reduces food intake [164,165].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [165]
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
How good are my data and what is the resolution?
Evans, P. R., & Murshudov, G. N. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913000061 · Cited by 4,697
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Postic, C., Shiota, M., Niswender, K. D., Jetton, T. L., Chen, Y., Moates, J. M., Shelton, K. D., Lindner, J., Cherrington, A. D., & Magnuson, M. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.1.305 · Cited by 1,302
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 4×
“This finding has not been observed in GIPR KO mouse models (9, 22, 32) or in other therapies targeting the GIP/GIPR axis (31).”
BackgroundMethodResultInfluential
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“However, controversy still exists as to whether it is best to therapeutically promote or inhibit GIP action for beneficial effects on glycemic control and body weight [929e931] as both GIPR agonists [932] and antagonists [933,934] have decreased body weight in preclinical studies as individual treatments, but also to…”
BackgroundTirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541
“In the presence of HSA, TZP right-shifts 81-fold (n = 5), while the potency of GLP-1(7-36) is unaltered (n = 24).”
InfluentialHow May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Adriaenssens, A. E., Biggs, E. K., Darwish, T., Tadross, J., Sukthankar, T., Girish, M., Polex-Wolf, J., Lam, B. Y., Zvetkova, I., Pan, W., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.013 · Cited by 324
“Gipr Is Expressed in Neurons and Glial Cells in Key Feeding Centers of the Brain Although two GIPR antagonistic antibodies have been reported (Killion et al., 2018; Ravn et al., 2013), neither has been used for immunohistochemical localization.”
BackgroundZhang, Q., Delessa, C. T., Augustin, R., Bakhti, M., Colldén, G., Drucker, D. J., Feuchtinger, A., Caceres, C. G., Grandl, G., Harger, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.015 · Cited by 322
Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
“However, it has been shown in animal models that GIP RAs potentiates GLP-1-induced weight loss and reduces food intake [164,165].”
BackgroundMechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
GPCR drug discovery: new agents, targets and indications
Lorente, J. S., Sokolov, A. V., Ferguson, G., Schiöth, H. B., Hauser, A. S., & Gloriam, D. E. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01139-y · Cited by 251
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Samms, R. J., Christe, M. E., Collins, K. A. L., Pirro, V., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., Cosgrove, R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146353 · Cited by 256
“A key finding of the current study is that tirzepatide ameliorated peripheral IR in a model of DIO.”
BackgroundGLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
“Collectively, genetic data linked to clinical phenotypes and pharmacological data from loss of GIPR activity support development of GIPR antagonist–GLP-1RA combinations, with MariTide demonstrating robust efficacy in preclinical 66,78 and phase I clinical testing 79 .”
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
“However, in rodents and non-human primates, loss of GIP function via pharmacological antagonism or whole-body genetic knockout reduces accumulation of adipose mass and is protective against diet-induced obesity 36,38,47,48 .”
InfluentialThe expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
“Paradoxically, reduction of intestinal GIP expression [93], GIPR antagonism [94] or genetic elimination of GIPR [95], also reduces food intake and promotes resistance to diet-induced obesity and weight loss in multiple species.”
Véniant, M. M., Lu, S.-C., Atangan, L., Komorowski, R., Stanislaus, S., Cheng, Y., Wu, B., Falsey, J. R., Hager, T., Thomas, V. A., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-023-00966-w · Cited by 218
“https://doi.org/10.1038/s42255-023-00966-w Pharmacological inhibition of GIPR with anti-GIPR antibodies prevented BW gain in DIO mice and obese cynomolgus monkeys 33 .”
InfluentialSelf-citationGIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Holst, J. J., & Rosenkilde, M. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa327 · Cited by 207
“e2710 J Clin Endocrinol Metab, August 2020, 105(8):e2710–e2716 https://academic.”
BackgroundResultInfluentialBorner, T., Geisler, C. E., Fortin, S. M., Cosgrove, R., Alsina-Fernandez, J., Dogra, M., Doebley, S., Sanchez-Navarro, M. J., Leon, R. M., Gaisinsky, J., et al. (2021) · Diabetes · doi:10.2337/db21-0459 · Cited by 202
Incretin hormones and type 2 diabetes
Nauck, M. A., & Müller, T. D. (2023) · Diabetologia · doi:10.1007/s00125-023-05956-x · Cited by 190
“Similar to GIP/GLP-1 receptor co-agonism, GLP-1 receptor agonism in combination with GIP receptor antagonism (either as co-therapy or using unimolecular formulations) improved glucose metabolism and decreased body weight in preclinical [99] and clinical studies [100].”
BackgroundSemaglutide reduces alcohol intake and relapse-like drinking in male and female rats
Aranäs, C., Edvardsson, C. E., Shevchouk, O. T., Zhang, Q., Witley, S., Blid Sköldheden, S., Zentveld, L., Vallöf, D., Tufvesson-Alm, M., & Jerlhag, E. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104642 · Cited by 158
Mayendraraj, A., Rosenkilde, M. M., & Gasbjerg, L. S. (2022) · Peptides · doi:10.1016/j.peptides.2022.170749 · Cited by 154
Killion, E. A., Chen, M., Falsey, J. R., Sivits, G., Hager, T., Atangan, L., Helmering, J., Lee, J., Li, H., Wu, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18751-8 · Cited by 151
“These include: (1) technical replicate samples derived from a pool of well-characterized human plasma (MTRX), (2) extracted water samples (process blanks) and solvent blanks; and (3) a cocktail of QC standards, carefully chosen not to interfere with the measurement of endogenous compounds, spiked into every analyzed s…”
BackgroundSelf-citationCampbell, J. E., Müller, T. D., Finan, B., DiMarchi, R. D., Tschöp, M. H., & D’Alessio, D. A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.010 · Cited by 149
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 152
“Neutralizing GIPR antibodies, which are presumably sequestered to the periphery, reduce body weight in an independent manner to food intake and modify energetic substrate utilization in vivo [33].”
BackgroundRecent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.838410 · Cited by 146
“While GIPR antagonism has only little effects to decrease body weight in DIO mice (181, 183–186), its combination with GLP-1R agonism decreases body weight beyond what is possible with either monotherapy alone (181).”
BackgroundInfluentialTargeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133
The Role of Incretins on Insulin Function and Glucose Homeostasis
Holst, J. J., Gasbjerg, L. S., & Rosenkilde, M. M. (2021) · Endocrinology · doi:10.1210/endocr/bqab065 · Cited by 124
“In contrast, in other experimental studies, GIP antagonists lowered body weight, particularly in combination with GLP-1 (76).”
ResultTanycytes control hypothalamic liraglutide uptake and its anti-obesity actions
Imbernon, M., Saponaro, C., Helms, H. C. C., Duquenne, M., Fernandois, D., Deligia, E., Denis, R. G. P., Chao, D. H. M., Rasika, S., Staels, B., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.06.002 · Cited by 124
Transforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170183 · Cited by 121
Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
Boer, G. A., & Holst, J. J. (2020) · Biology · doi:10.3390/biology9120473 · Cited by 152
Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition
Kaneko, K., Fu, Y., Lin, H.-Y., Cordonier, E. L., Mo, Q., Gao, Y., Yao, T., Naylor, J., Howard, V., Saito, K., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126107 · Cited by 106
“In agreement with a recent study (21), peripheral administration of Gipg013 did not reduce weight from the baseline but merely prevented weight gain in HFD-induced obese mice (Supplemental Figure 2, C–F).”
BackgroundGut hormone co-agonists for the treatment of obesity: from bench to bedside
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00812-z · Cited by 102
A survey of the mouse hindbrain in the fed and fasted states using single-nucleus RNA sequencing
Dowsett, G. K. C., Lam, B. Y. H., Tadross, J. A., Cimino, I., Rimmington, D., Coll, A. P., Polex-Wolf, J., Knudsen, L. B., Pyke, C., & Yeo, G. S. H. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101240 · Cited by 98
“Even with dual agonism of GIPR and GLP1R showing an additional effect on weight loss in humans by reduction of food intake [39], the involvement of GIPR in controlling food intake and bodyweight is still not fully understood, with both antagonism of the receptor with an antibody and administration either centrally or…”
BackgroundThe role of GIP in α-cells and glucagon secretion
El, K., & Campbell, J. E. (2020) · Peptides · doi:10.1016/j.peptides.2019.170213 · Cited by 96
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
Jepsen, M. M., & Christensen, M. B. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1947240 · Cited by 96
Novikoff, A., O'Brien, S. L., Bernecker, M., Grandl, G., Kleinert, M., Knerr, P. J., Stemmer, K., Klingenspor, M., Zeigerer, A., DiMarchi, R., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101181 · Cited by 95
Killion, E. A., Lu, S.-C., Fort, M., Yamada, Y., Véniant, M. M., & Lloyd, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz002 · Cited by 94
Self-citationGlucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 112
Lu, S.-C., Chen, M., Atangan, L., Killion, E. A., Komorowski, R., Cheng, Y., Netirojjanakul, C., Falsey, J. R., Stolina, M., Dwyer, D., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100263 · Cited by 91
“In addition, BW loss was significantly enhanced in DIO mice and monkeys when anti-GIPR antibodies (Abs) were co-administered with GLP-1Ras.(21) These results support the development of single molecules that target multiple pathways for improving efficacy in treating obesity.”
BackgroundSelf-citationObesity and the kidney: mechanistic links and therapeutic advances
Yau, K., Kuah, R., Cherney, D. Z. I., & Lam, T. K. T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00951-7 · Cited by 91
Leveraging the Gut to Treat Metabolic Disease
Gimeno, R. E., Briere, D. A., & Seeley, R. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.014 · Cited by 83
The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review
Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174092 · Cited by 80
“Finally, the combination of GIPR antagonism and a GLP-1RA enhanced the observed weight loss in all animal models [119].”
BackgroundResultInfluentialAdriaenssens, A., Broichhagen, J., de Bray, A., Ast, J., Hasib, A., Jones, B., Tomas, A., Burgos, N. F., Woodward, O., Lewis, J., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.164921 · Cited by 77
The incretin/glucagon system as a target for pharmacotherapy of obesity
Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews · doi:10.1111/obr.13372 · Cited by 77
“GIP analogues that do not alter bodyweight when administered alone to mice with diet-induced obesity were found to enhance GLP-1-induced weight loss, reduce food intake, and prevent fat mass accumulation(126,127); however, similar results have also been obtained with GIP antibodies.(128) The dual GLP-1R/GIPR agonist t…”
ResultThe Role of GIP Receptor in the CNS for the Pathogenesis of Obesity
Fukuda, M. (2021) · Diabetes · doi:10.2337/dbi21-0001 · Cited by 69
Physiological roles of the GIP receptor in murine brown adipose tissue
Beaudry, J. L., Kaur, K. D., Varin, E. M., Baggio, L. L., Cao, X., Mulvihill, E. E., Bates, H. E., Campbell, J. E., & Drucker, D. J. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.08.006 · Cited by 76
GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue
Campbell, J. E., Beaudry, J. L., Svendsen, B., Baggio, L. L., Gordon, A. N., Ussher, J. R., Wong, C. K., Gribble, F. M., D’Alessio, D. A., Reimann, F., et al. (2022) · Diabetes · doi:10.2337/db21-1166 · Cited by 68
Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170174 · Cited by 67
Pharmacological antagonism of the incretin system protects against diet-induced obesity
Svendsen, B., Capozzi, M. E., Nui, J., Hannou, S. A., Finan, B., Naylor, J., Ravn, P., D'Alessio, D. A., & Campbell, J. E. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.11.018 · Cited by 67
The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
Hayes, M. R., Borner, T., & De Jonghe, B. C. (2021) · Diabetes · doi:10.2337/dbi21-0004 · Cited by 64
“, GLP-1(7-36)], this compound was resistant to enzymatic degradation by dipeptidyl peptidase IV.”
BackgroundRecent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors
Suzuki, R., Brown, G. A., Christopher, J. A., Scully, C. C. G., & Congreve, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00835 · Cited by 60
Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems
Yang, B., Gelfanov, V. M., El, K., Chen, A., Rohlfs, R., DuBois, B., Kruse Hansen, A. M., Perez-Tilve, D., Knerr, P. J., D'Alessio, D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101638 · Cited by 55
“This has led to the emergence of both GIPR agonizing peptides along with GIPR neutralizing antibodies [32,33] as potential therapeutics for obesity.”
BackgroundGabe, M. B. N., van der Velden, W. J. C., Gadgaard, S., Smit, F. X., Hartmann, B., Bräuner‐Osborne, H., & Rosenkilde, M. M. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13289 · Cited by 55
Yuliantie, E., Darbalaei, S., Dai, A., Zhao, P., Yang, D., Sexton, P. M., Wang, M.-W., & Wootten, D. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114001 · Cited by 53
Brain control of energy homeostasis: implications for anti-obesity pharmacotherapy
Johansen, V. B. I., Petersen, J., Lund, J., Mathiesen, C. V., Fenselau, H., & Clemmensen, C. (2025) · Cell · doi:10.1016/j.cell.2025.06.010 · Cited by 53
Gutgesell, R. M., Khalil, A., Liśkiewicz, A., Maity‐Kumar, G., Novikoff, A., Grandl, G., Liśkiewicz, D., Coupland, C., Karaoglu, E., Akindehin, S., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01294-x · Cited by 62
“Here, to test this hypothesis, we set out to assess the metabolic effects of two validated GIPR antagonists 22,23 in mice with whole-body or targeted deletion of Gipr .”
Kizilkaya, H. S., Sørensen, K. V., Kibsgaard, C. J., Gasbjerg, L. S., Hauser, A. S., Sparre-Ulrich, A. H., Grarup, N., & Rosenkilde, M. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.749607 · Cited by 52
Kaur, M., & Misra, S. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03646-0 · Cited by 51
Ceddia, R. P., & Collins, S. (2020) · Clinical Science · doi:10.1042/cs20190579 · Cited by 52
Samms, R. J., Sloop, K. W., Gribble, F. M., Reimann, F., & Adriaenssens, A. E. (2021) · Diabetes · doi:10.2337/dbi21-0002 · Cited by 49
“The relative contribution of GIPR signaling to the success of GIPR/GLP-1R dual agonists in altering energy balance is still uncertain, as, in preclinical models, both GIPR agonists and antagonists enhance appetite suppression and weight loss mediated by GLP-1RA treatment in mice (16,33,36).”
BackgroundKnerr, P. J., Mowery, S. A., Finan, B., Perez-Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2020) · Peptides · doi:10.1016/j.peptides.2019.170225 · Cited by 49
Borner, T., Tinsley, I. C., Doyle, R. P., Hayes, M. R., & De Jonghe, B. C. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15647 · Cited by 49
GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2192865 · Cited by 54
“monotherapy in obese mice and non-human primates [120].”
BackgroundPsaltis, J. P., Marathe, J., Nguyen, M. T., Le, R., Bursill, C. A., Marathe, C. S., Nelson, A. J., & Psaltis, P. J. (2024) · Medicinal Research Reviews · doi:10.1002/med.22070 · Cited by 51
“128 Therefore, GIP agonism and GIP antagonism appear to have similar effects.”
Tirzepatide for overweight and obesity management
Hamza, M., Papamargaritis, D., & Davies, M. J. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2436595 · Cited by 43
“Interestingly, pharmacological inhibition of the GIP receptor has also demonstrated effectiveness in preventing weight gain in animal models with obesity [28].”
Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
Tanday, N., Flatt, P. R., & Irwin, N. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15485 · Cited by 41
Gasbjerg, L. S., Rosenkilde, M. M., Meier, J. J., Holst, J. J., & Knop, F. K. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15216 · Cited by 41
“…combination approaches (e.g. combinations of GLP-1 and GIP analogues, or GLP-1 and amylin analogues, 132 or GLP-1 analogues and GIP receptor antagonists 58,121,122 ), where the dose ratios could be easily adjusted according to personalized needs, such as beneficial effects versus adverse effects.”
BackgroundEmerging role of GIP and related gut hormones in fertility and PCOS
Moffett, R. C., & Naughton, V. R. (2020) · Peptides · doi:10.1016/j.peptides.2019.170233 · Cited by 44
Reagents and models for detecting endogenous GLP1R and GIPR
Ast, J., Broichhagen, J., & Hodson, D. J. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103739 · Cited by 40
GIP receptor agonism blocks chemotherapy-induced nausea and vomiting
Borner, T., Reiner, B. C., Crist, R. C., Furst, C. D., Doebley, S. A., Halas, J. G., Ai, M., Samms, R. J., Jonghe, B. C. D., & Hayes, M. R. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101743 · Cited by 41
Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease
Wolfe, M. M., Boylan, M. O., & Chin, W. W. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf006 · Cited by 48
“Killion et al (149) compared the effects of a long-acting GIP agonist with a GIPR mAb on body weight and fat mass in mice.”
InfluentialThe glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system
Adriaenssens, A. E., Gribble, F. M., & Reimann, F. (2020) · Peptides · doi:10.1016/j.peptides.2019.170194 · Cited by 40
Gut peptide regulation of food intake – evidence for the modulation of hedonic feeding
Woodward, O. R. M., Gribble, F. M., Reimann, F., & Lewis, J. E. (2022) · The Journal of Physiology · doi:10.1113/jp280581 · Cited by 40
Liébana-García, R., López‐Almela, I., Olivares, M., Romaní‐Pérez, M., Manghi, P., Torres-Mayo, A., Tolosa-Enguís, V., Flor‐Duro, A., Bullich‐Vilarrubias, C., Rubio, T., et al. (2025) · Nature Microbiology · doi:10.1038/s41564-025-01989-7 · Cited by 53
“Obesity development can be attenuated by neutralizing antibodies to GIP or by GIP receptor antagonists 39,40 .”
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 43
“Indeed, therapeutic approaches based on immunization against GIP [253,254] or GIP antagonism showed promising anti-obesogenic effects in mice [255] and in humans [256,257].”
BackgroundBoer, G. A., Keenan, S. N., Miotto, P. M., Holst, J. J., & Watt, M. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00646.2020 · Cited by 38
Gut hormone GIP induces inflammation and insulin resistance in the hypothalamus
Fu, Y., Kaneko, K., Lin, H.-Y., Mo, Q., Xu, Y., Suganami, T., Ravn, P., & Fukuda, M. (2020) · Endocrinology · doi:10.1210/endocr/bqaa102 · Cited by 38
Single-Cell Mapping of GLP-1 and GIP Receptor Expression in the Dorsal Vagal Complex
Ludwig, M. Q., Todorov, P. V., Egerod, K. L., Olson, D. P., & Pers, T. H. (2021) · Diabetes · doi:10.2337/dbi21-0003 · Cited by 38
“Interestingly, both peripherally and centrally administered GIPR antagonists have been shown to protect against obesity in rodents and nonhuman primates (7,8), indicating that the cellular mechanisms through which GIPR signaling improves metabolic function remain undefined.”
BackgroundJensen, M., Sanni, S. J., Riber, D., Holst, J. J., ROSENKILDE, M. M., & Sparre‐Ulrich, A. H. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102006 · Cited by 42
Gabe, M. B. N., van der Velden, W. J. C., Smit, F. X., Gasbjerg, L. S., & Rosenkilde, M. M. (2020) · Peptides · doi:10.1016/j.peptides.2019.170224 · Cited by 37
Gut peptide regulation of food intake - evidence for the modulation of hedonic feeding.
Woodward, O. R. M., Gribble, F. M., Reimann, F. M., & Lewis, J. E. (2021) · Apollo (University of Cambridge) · doi:10.17863/cam.74301 · Cited by 37
GIP’s involvement in the pathophysiology of type 2 diabetes
Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170178 · Cited by 35
Liu, C. M., Killion, E. A., Hammoud, R., Lu, S.-C., Komorowski, R., Liu, T., Kanke, M., Thomas, V. A., Cook, K. D., Sivits, G. N., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01295-w · Cited by 44
“We used an mGIPR-Ab that fully neutralizes GIPR activity in vitro and prevents body weight gain in obese mice when dosed systemically 17 .”
InfluentialSelf-citationThe gut hormone receptor GIPR links energy availability to the control of hematopoiesis
Pujadas, G., Varin, E. M., Baggio, L. L., Mulvihill, E. E., Bang, K. W. A., Koehler, J. A., Matthews, D., & Drucker, D. J. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101008 · Cited by 35
Genetic disruption of the Gipr in Apoe−/− mice promotes atherosclerosis
Pujadas, G., Baggio, L. L., Kaur, K. D., McLean, B. A., Cao, X., & Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101586 · Cited by 34
Stimulating intestinal GIP release reduces food intake and body weight in mice
Lewis, J. E., Nuzzaci, D., James-Okoro, P.-P., Montaner, M., O’Flaherty, E. A. A., Darwish, T., Hayashi, M., Liberles, S. D., Hornigold, D. C., Naylor, J., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101945 · Cited by 37
“Indeed, GIPR antagonists improve body weight and glucose homeostasis in mice and non-human primates and enhance leptin ’ s anorectic effect in high fat diet (HFD)- induced obese mice [7,8].”
BackgroundKaneko, S. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.1.10 · Cited by 58
“Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry.”
BackgroundMethodCNS-targeting pharmacological interventions for the metabolic syndrome
Stemmer, K., Müller, T. D., DiMarchi, R. D., Pfluger, P. T., & Tschöp, M. H. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129195 · Cited by 36
“Surprisingly, the pharmacological targeting of the GIP receptor (GIPR) by agonists (130, 136–138) as well as by antagonists (139, 140) led to body weight loss in obese rodents.”
BackgroundRecent advances of GIP and future horizons
Holst, J. J., & Rosenkilde, M. M. (2020) · Peptides · doi:10.1016/j.peptides.2019.170230 · Cited by 33
Lee, S., Yang, K. J. Z., Brun, P., Silvaroli, J. A., Yuen, J. J., Shmarakov, I. O., Jiang, H., FERANIL, J. B., Li, X., Lackey, A. I., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay8937 · Cited by 35
“Genetically modified mice lacking an intact cell surface receptor for GIP are protected from obesity associated with high-fat diet consumption, leptin deficiency, and ovariectomy ( 43 – 47 ).”
Dang, Y., Hua, W., Zhang, X., Sun, H., Zhang, Y., Yu, B., Wang, S., Zhang, M., Kong, Z., Pan, D., et al. (2023) · Basic Research in Cardiology · doi:10.1007/s00395-022-00975-y · Cited by 33
Hasib, A. (2020) · Clinical Medicine Insights: Endocrinology and Diabetes · doi:10.1177/1179551420905844 · Cited by 29
Relevance and consequence of chronic inflammation for obesity development
Rück, L., Wiegand, S., & Kühnen, P. (2023) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-023-00170-6 · Cited by 35
“In the liver, a reduction of GIP ameliorates lipid accumulation and lowers the expression of markers of inflammation [235, 240, 241].”
Background360-Degree Perspectives on Obesity
Cuciureanu, M. D., Caratașu, C.-C., Gabrielian, L., Frăsinariu, O. E., Checheriță, L. E., Trandafir, L. M., Stanciu, G. D., Szilagyi, A., Pogonea, I., Bordeianu, G., et al. (2023) · Medicina · doi:10.3390/medicina59061119 · Cited by 37
Barriers and Solutions for Prescribing Obesity Pharmacotherapy
Fujioka, K., & Harris, S. R. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.02.007 · Cited by 28
Pelle, M. C., Provenzano, M., Zaffina, I., Pujia, R., Giofrè, F., Lucà, S., Andreucci, M., Sciacqua, A., & Arturi, F. (2021) · Life · doi:10.3390/life12010029 · Cited by 28
Irwin, N., Gault, V. A., O’Harte, F. P. M., & Flatt, P. R. (2020) · Peptides · doi:10.1016/j.peptides.2019.170203 · Cited by 27
Fang, X., Du, Z., Duan, C., Zhan, S., Wang, T., Zhu, M., Shi, J., Meng, J., Zhang, X., Yang, M., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118966 · Cited by 29
Metadata
- Authors
- Killion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., Lu, S.-C., Kurzeja, R. J. M., Sivits, G., Lin, J., Chen, Q., Wang, Z., Thibault, S. A., Abbott, C. M., Meng, T., Clavette, B., Murawsky, C. M., Foltz, I. N., Rottman, J. B., Hale, C., Véniant, M. M., & Lloyd, D. J.
- Affiliations
- Amgen (United States) (US)
- Amgen Research, Department of Cardiometabolic Disorders, Amgen Inc., One Amgen Center Dr., Thousand Oaks, CA 91320, USA.
- Amgen Research, Department of Therapeutic Discovery, Amgen Inc., One Amgen Center Dr., Thousand Oaks, CA 91320, USA.
- Amgen Research, Department of Therapeutic Discovery, Amgen Inc., 7990 Enterprise Street, Burnaby, BC V5A 1V7, Canada.
- Corresponding author
- Killion, Elizabeth A.
- Wang, Jinghong
- Yie, Junming
- Lloyd, David J.
- ORCID
- Killion, Elizabeth A.
- Wang, Jinghong
- Yie, Junming
- Shi, Stone D.-H.
- Bates, Darren
- Min, Xiaoshan
- Komorowski, Renee
- Deng, Liying
- Lu, Shu-Chen
- Kurzeja, Robert J. M.
- Sivits, Glenn
- Chen, Qing
- Wang, Zhulun
- Thibault, Stephen A.
- Abbott, Christina M.
- Clavette, Brandon
- Murawsky, Christopher M.
- Rottman, James B.
- Hale, Clarence
- Véniant, Murielle M.
- Lloyd, David J.
- Venue
- Science Translational Medicine
- Published
- 2018-12-19
- Volume
- 10
- Issue
- 472
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2904833368
- Cited by
- 237
- References
- 42
- Citations by year
- 2026: 32 · 2025: 33 · 2024: 33 · 2023: 28 · 2022: 31 · 2021: 31 · 2020: 20 · 2019: 27
- FWCI
- 11.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen Inc
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GIP receptor antagonist, obesity, diet-induced obesity, GLP-1 receptor agonists, combination therapy, weight loss, dietary intake, respiratory exchange ratio, non-human primates, pancreatic beta cells, obesity treatment
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Antibodies, Diet, Drug Therapy, Combination, Glucagon-Like Peptides, Feeding Behavior, Gastric Inhibitory Polypeptide, Humans, Immunoglobulin Fc Fragments, Mice, Obese, Obesity, Primates, Receptors, Gastrointestinal Hormone, Recombinant Fusion Proteins, Respiration, Weight Gain, Weight Loss, Adipocytes, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.